Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The Forever Healthy Foundation launched evipedia.ai, a free, continuously updated encyclopedia of evidence reviews covering 500+ health and longevity interventions. Built using audit-based AI methodology designed to reduce hallucination and bias, the resource addresses the fragmentation and marketing noise that obscures reliable evidence in longevity research.
NewLimit has raised $435 million and accelerated its lead epigenetic reprogramming therapy into human trials next year—a timeline compressed from over a decade away due to unexpectedly compelling preclinical data in liver cells. The approach targets aging at the cellular level to restore function rather than halt time, positioning epigenetic intervention as a potential foundation for addressing multiple age-related diseases simultaneously.
InsideTracker launched Terra, an AI platform that integrates wearable data, blood biomarkers, and health apps to deliver personalized recommendations for wellness and healthcare businesses. The shift reflects growing consumer demand for evidence-based outcomes rather than generic wellness claims, reshaping how the industry validates health interventions.
A strategic partnership between Deep Science Ventures and Medicines Discovery Catapult targets the blood-brain barrier as a systemic bottleneck limiting neurological drug delivery. Over 40% of the global population faces neurological conditions, yet the ability to transport therapeutics across this selective barrier remains the primary constraint, not the therapeutic discovery itself.
AEON Clinic in Dubai offers physician-supervised IV nutrient therapies and NAD+ treatments as part of a broader shift toward personalized health optimization focused on healthspan rather than lifespan. The clinic positions these interventions within longer-term health strategies rather than as standalone wellness experiences, reflecting emerging sophistication in how longevity medicine is being integrated into clinical practice.
The Allen Institute's $400 million Brain Health accelerator shifts neurodegeneration research from protein-focused investigations toward cellular and circuit-level mapping in human brain tissue. This approach targets the architectural vulnerabilities where disease actually initiates, rather than pursuing single molecular culprits that have historically failed to yield effective therapies.
C2N Diagnostics is expanding blood-based biomarker testing for Alzheimer's pathology across Latin America and the Caribbean through a partnership with SouthGenetics. This addresses a critical gap: regions with aging populations, limited specialist capacity, and constrained imaging infrastructure now have earlier access to amyloid assessment before cognitive decline becomes clinically apparent.
Voyager Therapeutics has received FDA clearance to initiate clinical testing of VY1706, a single-dose intravenous gene therapy designed to reduce tau protein accumulation in the brains of early Alzheimer's disease patients. The approach uses an engineered viral vector to deliver a tau-targeting genetic payload directly to neural tissue, representing a mechanistic departure from current symptomatic treatments.
Elecoglipron (AZD5004/ECC5004), an oral once-daily GLP-1 receptor agonist developed by Eccogene and AstraZeneca, will present Phase 1b and Phase 2b clinical trial data at the American Diabetes Association Scientific Sessions in June 2026. The candidate targets weight loss and type 2 diabetes management with the practical advantage of no food or water restrictions.
Augustine Therapeutics will present preclinical data on an HDAC6 inhibitor for heart failure with preserved ejection fraction at the American Diabetes Association conference. The selective HDAC6 inhibitor represents a mechanistic approach to a prevalent cardiometabolic phenotype where ejection fraction remains normal despite functional impairment.
Corsair Pharma's transdermal patch delivered stable treprostinil levels over 24 hours with minimal fluctuation in early human trials, demonstrating pharmacokinetic performance comparable to injectable alternatives. This delivery method addresses a significant clinical gap in pulmonary hypertension treatment by reducing dosing frequency and injection burden while maintaining therapeutic consistency.
NanoDetection and Oligomerix have partnered to develop diagnostic tests that differentiate tau pathologies underlying Alzheimer's disease and related dementias using a panel of nine proprietary antibodies. Early validation across cerebrospinal fluid and other human samples suggests these tests could enable earlier, more precise detection of distinct tau species and their aggregation patterns.